DENTSPLY SIRONA (NASDAQ:XRAY) Releases FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.400-1.500 for the period, compared to the consensus earnings per share estimate of 1.490. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.7 billion.

DENTSPLY SIRONA Price Performance

XRAY traded down $0.09 on Thursday, reaching $12.71. The company had a trading volume of 6,878,332 shares, compared to its average volume of 4,774,693. The company has a fifty day moving average of $12.35 and a 200-day moving average of $12.47. The company has a market capitalization of $2.54 billion, a P/E ratio of -2.88, a PEG ratio of 1.01 and a beta of 1.01. The company has a current ratio of 1.47, a quick ratio of 0.99 and a debt-to-equity ratio of 1.36. DENTSPLY SIRONA has a one year low of $9.85 and a one year high of $19.03.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 17.10% and a negative net margin of 24.34%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts anticipate that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were issued a $0.16 dividend. The ex-dividend date was Friday, December 26th. This represents a $0.64 annualized dividend and a dividend yield of 5.0%. DENTSPLY SIRONA’s dividend payout ratio is -14.48%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on XRAY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Robert W. Baird dropped their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Tuesday, December 16th. JPMorgan Chase & Co. reduced their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Barclays started coverage on DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price target on the stock. Finally, Zacks Research lowered DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a research note on Monday, November 10th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA presently has a consensus rating of “Hold” and an average target price of $14.46.

Insider Activity at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier sold 82,200 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.50% of the stock is currently owned by company insiders.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Q4 net sales came in above estimates—$961M (+6.2% y/y, +2.5% constant currency)—a top‑line beat that initially pushed the stock higher. Dentsply Sirona’s (NASDAQ:XRAY) Q4 CY2025 sales top estimates, stock soars
• Positive Sentiment: Company announced a ~$120M annual redirection of resources into a Return‑to‑Growth plan (innovation, clinical & sales education) and struck new distribution agreements—these moves are intended to boost medium‑term organic growth. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Neutral Sentiment: Management removed the dividend and will redeploy capital toward debt reduction and share repurchases—this shifts near‑term yield away from investors but can strengthen the balance sheet and EPS over time. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Neutral Sentiment: Issued FY2026 adjusted EPS guidance of $1.40–$1.50 (around the consensus) and revenue guidance of $3.5B–$3.6B. The EPS range is near Street expectations, but revenue guidance is below consensus. Press Release / Slide Deck
• Negative Sentiment: Adjusted EPS of $0.27 missed the Zacks/consensus estimate of $0.28 by $0.01, which can disappoint short‑term traders focused on beats/misses. Dentsply International (XRAY) Q4 Earnings Miss Estimates
• Negative Sentiment: GAAP results included a $146M net loss (diluted loss per share $0.74) driven by ~$144M of goodwill and intangible impairments—a one‑time charge that hits reported profitability and raises questions about past M&A. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Negative Sentiment: Halper Sadeh LLC has launched an investor inquiry alleging potential fiduciary breaches by officers/directors, which could lead to distractions, legal costs or governance scrutiny. HALPER SADEH LLC ENCOURAGES DENTSPLY SIRONA INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Hedge Funds Weigh In On DENTSPLY SIRONA

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after buying an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC lifted its position in DENTSPLY SIRONA by 0.9% during the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock worth $129,445,000 after acquiring an additional 92,868 shares during the last quarter. State Street Corp lifted its position in DENTSPLY SIRONA by 5.5% during the 2nd quarter. State Street Corp now owns 7,099,906 shares of the medical instruments supplier’s stock worth $113,868,000 after acquiring an additional 369,876 shares during the last quarter. Armistice Capital LLC boosted its holdings in DENTSPLY SIRONA by 1,044.0% during the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after acquiring an additional 5,234,587 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after purchasing an additional 4,003,606 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.